tbuckley/cabot-search huggingface dataset:
Tumor-Localized Interleukin-2 and Interleukin-12 Combine with Radiation Therapy to Safely Potentiate Regression of Advanced Malignant Melanoma in Pet Dogs
Authors: Jordan A. Stinson, Matheus Moreno P. Barbosa, Allison Sheen, Noor Momin, Elizabeth Fink, Jordan Hampel, Kim A. Selting, Rebecca L. Kamerer, Keith L. Bailey, Karl D. Wittrup, Timothy M. Fan
Journal: Clinical Cancer Research (2024)

Cytokines IL2 and IL12 exhibit potent anticancer activity but suffer a narrow therapeutic window due to off-tumor immune cell activation. Engineering cytokines with the ability to bind and associate with tumor collagen after intratumoral injection potentiated response without toxicity in mice and was previously safe in pet dogs with sarcoma. Here, we sought to test the efficacy of this approach in dogs with advanced melanoma.
Glutamine metabolic competition drives immunosuppressive reprogramming of intratumour GPR109A<sup>+</sup>myeloid cells to promote liver cancer progression
Authors: Yang Yang, Tianduo Pei, Chaobao Liu, Mingtao Cao, Xiaolin Hu, Jie Yuan, Fengqian Chen, Bao Guo, Yuemei Hong, Jibin Liu, Bin Li, Xiaoguang Li, Hui Wang
Journal: Gut (2024)

Objective The metabolic characteristics of liver cancer drive considerable hurdles to immune cells function and cancer immunotherapy. However, how metabolic reprograming in the tumour microenvironment impairs the antitumour immune response remains unclear. Design Human samples and multiple murine models were employed to evaluate the correlation between GPR109A and liver cancer progression. GPR109A knockout mice, immune cells depletion and primary cell coculture models were used to determine the regulation of GPR109A on tumour microenvironment and identify the underlying mechanism responsible for the formation of intratumour GPR109A + myeloid cells. Results We demonstrate that glutamine shortage in liver cancer tumour microenvironment drives an immunosuppressive GPR109A + myeloid cells infiltration, leading to the evasion of immune surveillance. Blockade of GPR109A decreases G-MDSCs and M2-like TAMs abundance to trigger the antitumour responses of CD8 + T cells and further improves the immunotherapy efficacy against liver cancer. Mechanistically, tumour cells and tumour-infiltrated myeloid cells compete for glutamine uptake via the transporter SLC1A5 to control antitumour immunity, which disrupts the endoplasmic reticulum (ER) homoeostasis and induces unfolded protein response of myeloid cells to promote GPR109A expression through IRE1α/XBP1 pathway. The restriction of glutamine uptake in liver cancer cells, as well as the blockade of IRE1α/XBP1 signalling or glutamine supplementation, can eliminate the immunosuppressive effects of GPR109A + myeloid cells and slow down tumour progression. Conclusion Our findings identify the immunometabolic crosstalk between liver cancer cells and myeloid cells facilitates tumour progression via a glutamine metabolism/ER stress/GPR109A axis, suggesting that GPR109A can be exploited as an immunometabolic checkpoint and putative target for cancer treatment.
Drug-induced Liver Injury in Latin America: 10-year Experience of the Latin American DILI (LATINDILI) Network
Authors: Fernando Bessone, Nelia Hernandez, Inmaculada Medina-Caliz, Miren García-Cortés, María I Schinoni, Manuel Mendizabal, Daniela Chiodi, Vinicius Nunes, Ezequiel Ridruejo, Ximena Pazos, Genario Santos, Eduardo Fassio, Raymundo Parana, Virginia Reggiardo, Hugo Tanno, Adriana Sanchez, Federico Tanno, Pedro Montes, Martin Tagle, Marco Arrese, Javier Brahm, Marcos Girala, M Isabel Lizarzabal, Enrique Carrera, Alina Zerega, Carla Bianchi, Laura Reyes, Daina Arnedillo, Antonella Cordone, Gisela Gualano, Fernanda Jaureguizahar, Gabriel Rifrani, Mercedes Robles-Díaz, Aida Ortega-Alonso, José M Pinazo-Bandera, Camilla Stephens, Judith Sanabria-Cabrera, Elvira Bonilla-Toyos, Hao Niu, Ismael Alvarez-Alvarez, M Isabel Lucena, Raul J Andrade
Journal: Clinical Gastroenterology and Hepatology (2024)
Centering the female athlete voice in a sports science research agenda: a modified Delphi survey with Team USA athletes
Authors: Julie McCleery, Ellie Diamond, Rose Kelly, Longxi Li, Kathryn E Ackerman, William M Adams, Emily Kraus
Journal: British Journal of Sports Medicine (2024)

Objectives To co-construct a sports medicine and exercise science research and translational agenda with Team USA elite female athletes serving as the experts on their health, performance and well-being. Methods 40 Team USA female athletes across sports disciplines participated in an online, anonymous, modified Delphi survey by ranking topics on a Likert scale (1=‘strongly disagree’ and 5=‘strongly agree’) and providing qualitative justification regarding whether they believed having more information and research on each topic would support their athletic performance, health and well-being. After each Delphi round, quantitative rankings of topics and qualitative justifications were analysed, informing revisions to the list of topics for review in the subsequent round. Researchers provided athletes with a detailed report of findings and revisions following each round. Results The final list contained 14 ranked topics. The top five were menstrual cycle symptoms (4.58±0.74), recovery (4.58±0.59), birth control (4.55±0.89), mental health (4.50±0.55) and fueling and the menstrual cycle (4.43±0.74). New topics originating from athletes included recovery, menstrual cycle symptoms, fueling and the menstrual cycle, mental health and sports performance, team dynamics, and institutionalised sexism. Conclusion This is the first study to co-construct a research and translational agenda with Team USA elite female athletes. The list of sports science research topics developed by focusing on elite female athletes’ voices lays the foundation for future research and provides valuable insight into the specific needs of female athletes.
High rates of respiratory illnesses upon arrival: lessons from Team USA at the Santiago 2023 Pan American and Parapan American Games
Authors: Eric G Post, Travis Anderson, Olivia Samson, Ashley N Triplett, Alexis D Gidley, Steven S Isono, Jennifer Watters, Amber T Donaldson, Jonathan T Finnoff, William M Adams
Journal: British Journal of Sports Medicine (2024)

Objective To describe the incidence and characteristics of injuries and illnesses among Team USA athletes competing at the Santiago 2023 Pan American Games (PAG) and Parapan American Games (PPAG), with a particular focus on the incidence of respiratory illnesses and on injuries for sports new to the Olympic and Paralympic programmes. Methods Illnesses and injuries occurring among the 870 Team USA athletes competing in the Santiago 2023 PAG or PPAG were documented within Team USA’s Injury and Illness Surveillance system. Illness and injury incidence per 1000 athlete-days (ADs) and incidence ratios (IR) were calculated, both with 95% CIs. Results Illness (IR 2.5, 95% CI 1.6, 3.9) and injury (IR 1.8, 95% CI 1.3, 2.5) rates were greater during PPAG compared with PAG. Illness rates were higher in the pre-opening ceremony period compared with the competition period for both PAG (IR 2.7, 95% CI 1.1, 5.9) and PPAG (IR 1.9, 95% CI 0.9, 3.8). Respiratory illness was the most common illness with 3.2% and 8.9% of all Team USA athletes reporting a respiratory illness during the PAG and PPAG, respectively. Sports that are relatively new to the Olympic/Paralympic programmes exhibited the highest injury rates during the Games: breaking (250.0 (91.7, 544.2) per 1000 ADs), Para taekwondo (93.8 (19.3, 274.0) per 1000 ADs) and surfing (88.9 (24.2, 227.6) per 1000 ADs). Conclusion Respiratory illness rates were the most common type of illness during both PAG and PPAG and were more likely to occur prior to competition starting. Our data have identified high injury risk populations (breaking, surfing, Para taekwondo) and timing (pre-opening ceremony period) for further risk factor analysis.
Non-diabetes status after diagnosis of impaired glucose tolerance and risk of long-term death and vascular complications: A post hoc analysis of the Da Qing Diabetes Prevention Outcome Study
Authors: Xin Qian, Jinping Wang, Qiuhong Gong, Yali An, Xinxing Feng, Siyao He, Xiaoping Chen, Wenjuan Wang, Lihong Zhang, Yuanchi Hui, Xiuwei Zhai, Bo Zhang, Yanyan Chen, Guangwei Li
Journal: PLoS Medicine (2024)

Background The association between years of non-diabetes status after diagnosis of impaired glucose tolerance (IGT) and the risk of long-term death and cardiovascular outcomes needed to be clarified. Methods and findings In this post hoc analysis, we included 540 individuals with IGT who participated in the original Da Qing Diabetes Prevention Study (DQDPS). In the DQDPS, all participants were diagnosed with IGT by a 75 g oral glucose tolerance test and randomized to intervention or control groups with a 6-year lifestyle intervention trial. After the completion of the trial, death, cardiovascular events, and microvascular complications were monitored over a 30-year follow-up. In this post hoc analysis, the Cox analysis assessed the extended risk of these outcomes in individuals who either remained non-diabetes status or progressed to diabetes at the end of 2, 4, and 6 years after diagnosis of IGT. In all participants, the difference in the cumulative incidence rate of the outcomes between the diabetes and non-diabetes group gradually increased over 30 years. Compared with the diabetes group, a significantly lower risk of all-cause death (hazard ratio [HR]: 0.74; 95% confidence interval [CI]: 0.57 to 0.97, p = 0.026), cardiovascular events (HR: 0.63; 95% CI: 0.49 to 0.82, p &lt; 0.001), and microvascular complications (HR: 0.62; 95% CI: 0.45 to 0.86, p = 0.004) first emerged in individuals who remained non-diabetes at the 4 years visit, whereas the significant risk reduction in cardiovascular death was first observed at the end of 6 years (HR: 0.56; 95% CI: 0.39 to 0.81, p = 0.002) after adjustment for age, sex, smoking status, BMI, systolic blood pressure, blood glucose, total cholesterol, intervention, and medications (including insulin plus oral hypoglycaemics, antihypertensives, and lipid-lowering agents). The results in the original intervention group alone were similar to the whole group. The main limitations of our study are the limited number of participants and the sole ethnicity of the Chinese population. Conclusions In this study, we observed that maintaining several years of non-diabetes status after IGT diagnosis was associated with a significant reduction in long-term risk of death and vascular complications, and for most of these outcomes, maintaining at least 4 years of non-diabetes status may be needed to achieve a significant risk reduction.
A fibroblast-dependent TGFβ1/sFRP2 noncanonical Wnt signaling axis promotes epithelial metaplasia in idiopathic pulmonary fibrosis
Authors: Max L. Cohen, Alexis N. Brumwell, Tsung Che Ho, Kiana Garakani, Genevieve Montas, Darren Leong, Vivianne W. Ding, Jeffrey A. Golden, Binh N. Trinh, David M. Jablons, Michael A. Matthay, Kirk D. Jones, Paul J. Wolters, Ying Wei, Harold A. Chapman, Claude Jourdan Le Saux
Journal: Journal of Clinical Investigation (2024)

Reciprocal interactions between alveolar fibroblasts and epithelial cells are crucial for lung homeostasis, injury repair, and fibrogenesis, but underlying mechanisms remain unclear. To investigate, we administered the fibroblast-selective TGF-β1 signaling inhibitor epigallocatechin gallate (EGCG) to interstitial lung disease (ILD) patients undergoing diagnostic lung biopsy and conducted single-cell RNA-Seq on spare tissue. Biopsies from untreated patients showed higher fibroblast TGF-β1 signaling compared with nondisease donor or end-stage ILD tissues. In vivo, EGCG downregulated TGF-β1 signaling and several proinflammatory and stress pathways in biopsy samples. Notably, EGCG reduced fibroblast secreted frizzled-related protein 2 (sFRP2), an unrecognized TGF-β1 fibroblast target gene induced near type II alveolar epithelial cells (AEC2s) in situ. Using AEC2-fibroblast coculture organoids and precision-cut lung slices (PCLSs) from nondiseased donors, we found TGF-β1 signaling promotes a spread AEC2 KRT17+ basaloid state, whereupon sFRP2 then activates a mature cytokeratin 5+ (Krt5+) basal cell program. Wnt-receptor Frizzled 5 (Fzd5) expression and downstream calcineurin signaling were required for sFRP2-induced nuclear NFATc3 accumulation and KRT5 expression. These findings highlight stage-specific TGF-β1 signaling in ILD and the therapeutic potential of EGCG in reducing idiopathic pulmonary fibrosis-related (IPF-related) transcriptional changes and identify TGF-β1/noncanonical Wnt pathway crosstalk via sFRP2 as a mechanism for dysfunctional epithelial signaling in IPF/ILD.
Prevalence of therapeutic use exemptions at the Olympic Games and Paralympic Games: an analysis of data from 2016 to 2022
Authors: Alan Vernec, David Healy, Tamar Banon, Andrea Petroczi
Journal: British Journal of Sports Medicine (2024)

The objectives of this study are to describe the prevalence of therapeutic use exemptions (TUEs) among athletes competing in four Olympic and four Paralympic games. The secondary objective was to present the prohibited substance and methods classes associated with TUEs.
Rational Protein Engineering to Enhance MHC-Independent T-cell Receptors
Authors: Ju-Fang Chang, Jack H. Landmann, Tien-Ching Chang, Mehmet Emrah. Selli, Yangdon Tenzin, John M. Warrington, Julie Ritchey, Yu-Sung Hsu, Michael Slade, Deepesh Kumar. Gupta, John F. DiPersio, Alex S. Holehouse, Nathan Singh
Journal: Cancer Discovery (2024)

Chimeric antigen receptor (CAR)-based therapies have pioneered synthetic cellular immunity but remain limited in their long-term efficacy. Emerging data suggest that dysregulated CAR-driven T-cell activation causes T-cell dysfunction and therapeutic failure. To re-engage the precision of the endogenous T-cell response, we designed MHC-independent T-cell receptors (miTCR) by linking antibody variable domains to T-cell receptor constant chains. Using predictive modeling, we observed that this standard "cut and paste" approach to synthetic protein design resulted in myriad biochemical conflicts at the hybrid variable-constant domain interface. Through iterative modeling and sequence modifications, we developed structure-enhanced miTCRs which significantly improved receptor-driven T-cell function across multiple tumor models. We found that 41BB costimulation specifically prolonged miTCR T-cell persistence and enabled improved leukemic control in vivo compared with classic CAR T cells. Collectively, we have identified core features of hybrid receptor structure responsible for regulating function. Significance: Improving the durability of engineered T-cell immunotherapies is critical to enhancing efficacy. We used a structure-informed design to evolve improved miTCR function across several models. This work underscores the central role of synthetic receptor structure in T-cell function and provides a framework for improved receptor engineering.
PP01.119 Real-World Use of Lurbinectedin in Patients with Small Cell Lung Cancer: Jazz EMERGE 402 Updated Analysis
Authors: Balazs Halmos, Philip Lammers, Mehul Patel, Iuliana Shapira, Leonid Shunyakov, Dennis Slater, Catherine Labbé, Navit Naveh, Anne Boccuti, Raj Hanvesakul, Wenyan Li, Badri Rengarajan, Firas Badin
Journal: Journal of Thoracic Oncology (2024)
PP01.99 Switching to Subcutaneous (SC) Atezolizumab After Intravenous (IV) Dosing: Evaluation of Atezolizumab Pharmacokinetics (PK) Using Population PK Modeling
Authors: Stephanie N. Liu, Phyllis Chan, Mathilde Marchand, Luis Herraez-Baranda, Rene Bruno, Pascal Chanu, Benjamin Wu
Journal: Journal of Thoracic Oncology (2024)
PP01.129 Effects of Preoperative Hematocrit Level on Perioperative Outcomes and Survival After Robotic-Assisted Video-Thoracoscopic Pulmonary Lobectomy
Authors: Sunny Kahlon, Carla C. Moodie, Joseph R. Garrett, Jenna R. Tew, Jobelle J.A.R. Baldonado, Jacques P. Fontaine, Eric M. Toloza
Journal: Journal of Thoracic Oncology (2024)
PP01.105 Early Detection of Non-Small Cell Lung Cancer using Electronic Health Record Data
Authors: Xiudi Li, Stephen J. Kuperberg, Qing Liu, Kumar Dahal, Clara-Lea Bonzel, Mary I. Jeffway, Tianrun Cai, Katherine P. Liao, Raquel Aguiar-Ibáñez, Yu-Han Kao, Melissa L. Santorelli, David C. Christiani, Tianxi Cai, Rui Duan
Journal: Journal of Thoracic Oncology (2024)
PP01.95 STK11, KEAP1, and KRAS mutation epidemiology and real-world outcomes in US patients with newly diagnosed metastatic non-small cell lung cancer
Authors: Firas Dabbous, Ching-Yu Wang, Rajrupa Ghosh, Kristin Hsieh, Daniel Simmons, Samuel Huse, Rami Jassim, Ferdinandos Skoulidis
Journal: Journal of Thoracic Oncology (2024)
PP01.104 Vebreltinib Efficacy In METex14 Mutant NSCLC With or Without Concurrent MET Amplification, MET GCN Status Distributions Compared With Public Databases
Authors: Mark M. Awad, Siddhartha Devarakonda, Jin-Li Yang, Yan Zhang, Lin Wu, Jie Hu, Zhe-Hai Wang, Jing-Hua Chen, Yun Fan, Jun Zhao, Jian Fang, None Yong Song, Xing-Ya Li, Maurice Perol, David Planchard, Pilar Garrido, Colin Lindsay, Melissa M. Moore, Alessandra Bulotta, Enric Carcereny Costa, Mariano Provencio, James Chih-Hsin Yang, David Spigel, Ernest Nadal, Kin-Hung Peony Yu, Yi-Long Wu
Journal: Journal of Thoracic Oncology (2024)
PP01.65 Efficacy and Safety of Dose-Escalated Alectinib in Patients with Metastatic ALK-positive NSCLC and CNS Relapse on Standard Dose Alectinib
Authors: Justin M. Cheung, Jiyoon Kang, Beow Y. Yeap, Jennifer L. Peterson, Andrew Do, Justin F. Gainor, Subba R. Digumarthy, Jessica J. Lin
Journal: Journal of Thoracic Oncology (2024)
PP01.130 Associations of Postoperative Hematocrit Levels and Postoperative Complications After Robotic-Assisted Pulmonary Lobectomy
Authors: Sunny Kahlon, None Carla C. Moodie, Joseph R. Garrett, Jenna R. Tew, Jobelle J.A.R. Baldonado, Jacques P. Fontaine, Eric M. Toloza
Journal: Journal of Thoracic Oncology (2024)
PP01.112 Treatment Patterns and Outcomes in Second-Line Advanced NSCLC Treated After Prior Platinum Chemotherapy and Immunotherapy Combination Therapy: A Real-World Study
Authors: Davey Daniel, Ran Gao, Shivani K. Mhatre, Charlotte Carroll, Riddhi Patel, Joseph Park, Daniel Haggstrom
Journal: Journal of Thoracic Oncology (2024)
PP01.85 A Phase 2/3 Study of Fianlimab, Cemiplimab, plus Chemotherapy Versus Cemiplimab plus Chemotherapy in First-Line Advanced Non-Small Cell Lung Cancer
Authors: Nashat Gabrail, Neil Faulkner, Santosh Nair, Emad Ibrahim, Daniel Brungs, Luke Dreisbach, Gopal Kunta, Jayakumar Mani, Maria Ghattas, Siyu Li, Mark Salvati, Israel Lowy, Tara Hiley, Matthew G. Fury, Luca Paoluzzi
Journal: Journal of Thoracic Oncology (2024)
PP01.88 REZILIENT3: Phase 3 Study of Zipalertinib plus Chemotherapy in Previously Untreated, Advanced Nonsquamous NSCLC Patients with EGFR Exon 20 Insertions
Authors: Helena A. Yu, Benjamin Besse, Makoto Nishio, Ying Cheng, Li Wei, Volker Wacheck, John V. Heymach
Journal: Journal of Thoracic Oncology (2024)
PP01.84 Tepotinib + Osimertinib in EGFR-mutant NSCLC with MET Amplification Following 1L Osimertinib: INSIGHT 2 Primary Analysis
Authors: Tae Min Kim, Valentina Guarneri, Pei Jye Voon, Boon Khaw Lim, Jin-ji Yang, Marie Wislez, Cheng Huang, Chong Kin Liam, Julien Mazieres, ye Mun Tho, Hidetoshi Hayashi, Nhung Nguyen, Puey Ling Chia, Filippo de Marinis, Jo Raskin, Qinghua Zhou, Giovanna Finocchiaro, Xiuning Le, Daniel Tan, Richard M. O’Hara, Sabine Brutlach, Aurora O’Brate, Svenja Adrian, Karin Berghoff, Barbara Ellers-Lenz, Niki Karachaliou, Yi-Long Wu
Journal: Journal of Thoracic Oncology (2024)
PP01.82 Tumor-Naïve Pre-Surgical ctDNA Detection is Prognostic in Stage I Lung Adenocarcinoma (LUAD), Associating with PD-L1 Positivity and High-Grade Histological Subtype
Authors: Tae Hee Hong, Soohyun Hwang, Chris Abbosh, Abhijit Dasgupta, Violeta Guthrie, Tiffany Hung, Jörg Bredno, Jill Walker, Xiaojin Shi, Tsveta Milenkova, Leora Horn, Joon Young Choi, Ho Yun Lee, Jong Ho Cho, Yong Soo Choi, Young Mog Shim, Darren Hodgson, Hong Kwan Kim, Myung-Ju Ahn
Journal: Journal of Thoracic Oncology (2024)
PP01.101 Estimated Cost of Adverse Events and Surgery for Resectable Non-Small Cell Lung Cancer Patients Receiving Neoadjuvant Nivolumab Plus Platinum-Doublet Chemotherapy
Authors: Sherry Wu, Paul Lozowicki, Stefano Lucherini, Sandra Milev, Saurabh Ray, Lien Vo
Journal: Journal of Thoracic Oncology (2024)
PP01.90 Real-world Demographics, Clinical Characteristics, Treatment Patterns and Clinical Outcomes for US Patients with Limited-Stage SCLC (LS-SCLC)
Authors: Anne C. Chiang, Rachel Salomonsen, Alice Wang, Rachel Holland, Ling Cai, Yang Xiao, Sam Sadow, Kieran Davey, Puneeth Iyengar
Journal: Journal of Thoracic Oncology (2024)
PP01.80 A retrospective observational study to evaluate patient-reported outcomes (PROs) in patients with metastatic ALK+ non-small cell lung cancer (NSCLC) treated with ALK inhibitors
Authors: Josh Biber, Yin Wan, Eric N. Churchill, Christopher G. Danes, Mark A. Socinski, Alexander I. Spira
Journal: Journal of Thoracic Oncology (2024)
PP01.59 Minimal Short-Term Mortality in a Diverse, Real-World Lung Cancer Screening Cohort
Authors: Mary E. Gwin, Tanushree Prasad, Urooj Wahid, Sheena Bhalla, Song Zhang, Jessica Lee, David H. Johnson, George Oliver, Lauren Vice, Cornelia Tan, Cynthia Watkins, David E. Gerber
Journal: Journal of Thoracic Oncology (2024)
PP01.87 A Phase 2/3 Study of Fianlimab plus Cemiplimab versus Cemiplimab in Patients with Advanced NSCLC with Tumors Expressing PD-L1 ≥50%
Authors: Neil Faulkner, Santosh Nair, Nashat Gabrail, Gopal Kunta, Emad Ibrahim, Luke Dreisbach, Daniel Brungs, Jayakumar Mani, Maria Ghattas, Siyu Li, Mark Salvati, Israel Lowy, Tara Hiley, Matthew G. Fury, Luca Paoluzzi
Journal: Journal of Thoracic Oncology (2024)
PP01.53 Patient-Reported Outcomes (PROs) in Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC): PERLA Trial Comparing First-Line Chemotherapy Plus Dostarlimab or Pembrolizumab
Authors: Martin Reck, Ana Laura Ortega Granados, Filippo de Marinis, Oren Meyers, Qin Shen, Lillian Cho, Susan Boklage, Winston Gouldin
Journal: Journal of Thoracic Oncology (2024)
PP01.20 Hospitalization patterns for immune-related adverse events in patients with NSCLC treated with immunotherapy vs chemo-immunotherapy
Authors: Adam Khorasanchi, Songzhu Zhao, Lai Wei, Mingjia Li, Kevin Ho, Hamzah Abu-Sbeih, Evelyn Goodyear, Austin Secor, Peter G. Shields, Kai He, Jacob Kaufman, Regan Memmott, Asrar Alahmadi, David Carbone, Gregory A. Otterson, Alexa Meara, Carolyn J. Presley, Dwight H. Owen
Journal: Journal of Thoracic Oncology (2024)
PP01.117 Real-World Effectiveness and Safety Profile of Lurbinectedin and Other Second-Line Treatments in Small Cell Lung Cancer
Authors: Apar Kishor Ganti, Victoria Allan, Patricia Prince, Adina Estrin, Nileesa Gautam, Dave Merola, Anne Boccuti, Badri Rengarajan, Cristina Baratta, Wenyan Li, Yanyan Cao, Elizabeth M. Poole
Journal: Journal of Thoracic Oncology (2024)
PP01.05 First-Line Treatment Patterns and Healthcare Resource Utilization among Non-Small Cell Lung Cancer Patients in Puerto Rico: The TREATLINES-ONCOLUNG Study
Authors: Karen J. Ortiz-Ortiz, Rafael Quintana, Axel Gierbolini-Bermúdez, Carlos R. Torres-Cintrón, Guillermo Tortolero-Luna, Edgar I. Miranda
Journal: Journal of Thoracic Oncology (2024)
PP01.09 Real-world clinical outcomes after progression with anti-PD(L)1 and chemotherapy in mNSCLC in the US
Authors: Stephen V. Liu, Anandaroop Dasgupta, Dominick Latremouille-Viau, Carmine Rossi, Pragya Rai, Fabrice Barlesi, Ticiana A. Leal
Journal: Journal of Thoracic Oncology (2024)
PP01.83 Treatment Sequencing in the VISION Study of Tepotinib in Patients with MET exon 14 (METex14) Skipping NSCLC
Authors: Frank Griesinger, Marina Garassino, Enriqueta Felip, Hiroshi Sakai, Xiuning Le, Remi Veillon, Egbert Smit, Jo Raskin, Michael Thomas, Myung-Ju Ahn, Matthew Lee, Soetkin Vlassak, Rolf Bruns, Andreas Johne, Paul K. Paik
Journal: Journal of Thoracic Oncology (2024)